» Articles » PMID: 25540596

Immunohistochemical Analysis of Aldehyde Dehydrogenase Isoforms and Their Association with Estrogen-receptor Status and Disease Progression in Breast Cancer

Overview
Publisher Dove Medical Press
Date 2014 Dec 26
PMID 25540596
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

In many types of tumors, especially breast tumors, aldehyde dehydrogenase (ALDH) activity has been used to identify cancer stem-like cells within the tumor. The presence and quantity of these cells are believed to predict the response of tumors to chemotherapy. Therefore, identification and eradication of these cells would be necessary to cure the patient. However, there are 19 different ALDH isoforms that could contribute to the enzyme activity. ALDH1A1 and ALDH1A3 are among the isoforms mostly responsible for the increased ALDH activity observed in these stem-like cells, although the main isoforms vary in different tissues and tumor types. In the study reported here, we attempted to determine if ALDH1A1 or ALDH1A3, specifically, correlate with tumor stage, grade, and hormone-receptor status in breast-cancer patients. While there was no significant correlation between ALDH1A1 and any of the parameters tested, we were able to identify a positive correlation between ALDH1A3 and tumor stage in triple-negative cancers. In addition, ALDH1A3 was negatively correlated with estrogen-receptor status. Our data suggest that ALDH1A3 could be utilized as a marker to identify stem-like cells within triple-negative tumors.

Citing Articles

Circular RNA LMBR1 inhibits bladder cancer progression by enhancing expression of the protein ALDH1A3.

Lv Y, Yuan Z, Chen D, Chen Z, Zhu X, Ying X Noncoding RNA Res. 2024; 9(4):1235-1248.

PMID: 39036604 PMC: 11259990. DOI: 10.1016/j.ncrna.2024.05.004.


Targeting the Retinoic Acid Pathway to Eradicate Cancer Stem Cells.

Brown G Int J Mol Sci. 2023; 24(3).

PMID: 36768694 PMC: 9916838. DOI: 10.3390/ijms24032373.


Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties of the Cancer Microenvironment Associated with Clinical Characteristics.

Garre E, Gustafsson A, Leiva M, Hakansson J, Stahlberg A, Kovacs A Cancers (Basel). 2022; 14(9).

PMID: 35565301 PMC: 9103124. DOI: 10.3390/cancers14092172.


Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma.

Antonowicz S, Bodai Z, Wiggins T, Markar S, Boshier P, Goh Y Nat Commun. 2021; 12(1):1454.

PMID: 33674602 PMC: 7935981. DOI: 10.1038/s41467-021-21800-5.


High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.

Nozaki Y, Motomura H, Tamori S, Kimura Y, Onaga C, Kanai S PLoS One. 2020; 15(7):e0235747.

PMID: 32658903 PMC: 7357771. DOI: 10.1371/journal.pone.0235747.


References
1.
Ali H, Dawson S, Blows F, Provenzano E, Pharoah P, Caldas C . Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res. 2011; 13(6):R118. PMC: 3326560. DOI: 10.1186/bcr3061. View

2.
Morimoto K, Kim S, Tanei T, Shimazu K, Tanji Y, Taguchi T . Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009; 100(6):1062-8. PMC: 11158415. DOI: 10.1111/j.1349-7006.2009.01151.x. View

3.
Black W, Vasiliou V . The aldehyde dehydrogenase gene superfamily resource center. Hum Genomics. 2009; 4(2):136-42. PMC: 3525204. DOI: 10.1186/1479-7364-4-2-136. View

4.
Currie M, Beardsley B, Harris G, Gunningham S, Dachs G, Dijkstra B . Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum Pathol. 2012; 44(3):402-11. DOI: 10.1016/j.humpath.2012.06.004. View

5.
Reuben J, Lee B, Gao H, Cohen E, Mego M, Giordano A . Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. Eur J Cancer. 2011; 47(10):1527-36. PMC: 3116032. DOI: 10.1016/j.ejca.2011.01.011. View